AIRS vs SSKN vs SKIN vs DERM

For growth investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger pick with 0. 6% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.

4%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: DERM returned -47. 4% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately -1481% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Journey Medical Corporation (DERM) carries a lower debt/equity ratio of 128% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), STRATA Skin Sciences, Inc.

(SSKN) is pulling ahead at 0. 6% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, AIRS leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AIRS leads at -1. 0% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DERM: 135.

0% to $11. 75.

In this comparison, AIRS (0.

1% yield) pays a dividend. SSKN, SKIN, DERM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIRS (Healthcare) and SSKN (Healthcare) and SKIN (Consumer Defensive) and DERM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.